ABIO Arca Biopharma, Inc. featured news, full reports, and detailed charts
Arca Biopharma, Inc. (ABIO) Wrap Up:
We have included or incorporated by reference into this Annual Report on Form 10-K statements that may constitute “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including “anticipate,” “believe,” “intends,” “estimates,” “expect,” “should,” “may,” “potential” and similar expressions. Such statements are based on our management’s current expectations and involve risks and uncertainties. Our actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors discussed in this Annual Report, including those set forth in this section under the caption “Item 1A. Risk Factors,” as well as those under “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and those discussed elsewhere in this Annual Report on Form 10-K. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f12%2f0001193125-08-053074.html#FIS_BUSINESS"ARCA biopharma, Inc. (ABIO:NASDAQ)
Snapshot of ARCA biopharma, Inc. (ABIO)
|
OPEN
$2.39
|
PREVIOUS CLOSE
$2.41
|
|
|
DAY HIGH
$2.40
|
DAY LOW
$2.21
|
|
|
52 WEEK HIGH
05/15/09 - $13.45
|
52 WEEK LOW
01/28/09 - $2.00
|
|
|
MARKET CAP
17.1M
|
AVERAGE VOLUME 3 mo
27.2K
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
7.6M
|
|
|
ABIO Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
ABIO Top Compensated Officers
Executives, Board Directors
Key developments for ARCA biopharma, Inc. (ABIO)
ARCA biopharma, Inc. announced its planned next steps in response to the May 29, 2009 Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for ARCA's New Drug Application (NDA) seeking approval for GencaroTM (bucindolol hydrochloride) for the treatment of patients with chronic heart failure. Following receipt of the CRL, the Company and the FDA have held a series of meetings to discuss how best to address the requirements identified in the CRL. The Company intends to submit a study protocol for review under the FDA's Special Protocol Assessment (SPA) process for the design of a clinical trial to assess the safety and efficacy of Gencaro in approximately 3,000 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro. ARCA anticipates that the proposed trial protocol will be a superiority comparison to the beta-blocker metoprolol CR/XL, which is approved for heart failure and other indications.
ARCA biopharma Inc. announced changes to its management team to reflect the company's recent change in commercial strategy to seek alternatives for the potential commercialization of Gencaro. Richard B. Brewer will assume the role of Chairman of the Board of Directors and resign as Chief Executive Officer. Michael R. Bristow, will become President and Chief Executive Officer, a position he previously held with ARCA prior to Mr. Brewer joining the company. Dr. Bristow will resign as Chairman but will remain a member of the Board of Directors. These changes will be effective on July 10, 2009.
On July 1, 2009, David G. Lowe, Ph.D. resigned as a member of the board of directors of ARCA biopharma Inc. for reasons unrelated to the conduct of the companys business. Dr. Lowes resignation is not due to any disagreement with the company.
ABIO Competitors
| Company | Last | Change | |
| No competitor information is available for ABIO. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | ABIO | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | 1.0x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
ABIO |
||
ABIO transactions
| Type Date |
Target |
|
Private Placement
October 18, 2009 |
-- |